The Varying Benefits of Two Years Automated Insulin Delivery System Use on Continuous Glucose Monitoring Profiles in Children and Adolescents with Type 1 Diabetes
Background: Automated insulin delivery (AID) systems are recommended for youths with type 1 diabetes, but real-world longitudinal data remains limited despite increasing use. This study evaluates the effect of 2 years of AID use on continuous glucose monitoring (CGM) profiles and body mass index (BMI) development. Methods: Data from individuals with type 1 diabetes aged <18 years, diabetes duration >3 months, and AID use of >3 months from the Diabetes Prospective Follow-up (DPV) Registry between 2019 and 2025 were analyzed. CGM and HbA1c were required at the last documented time in range (TIR) (±90 days; follow-up) and 2 years earlier (±90 days; baseline). Changes were investigated using adjusted regression models with repeated measurements. Findings: Data from 2486 participants (baseline: median age: 11.9 years, diabetes duration: 5.0 years, 53% male) were analyzed over ∼23 months. The largest gains occurred in time in tight range (TiTR) (42.4% [95% confidence interval: 41.0–43.7] to 50.1% [48.8–51.4]; P < 0.001) and coefficient of variation (CV) (32.9 [32.0–33.7] to 29.5 [28.7–30.2]; P < 0.001). HbA1c (7.3% [7.2–7.3] to 7.2 [7.1–7.2]; P < 0.001), TIR (64.5% [63.9–65.1] to 66.7% [66.1–67.3]; P < 0.001), and mean sensor glucose (SG) (161.0 mg/dL [158.4–163.5] to 155.5 mg/dL [153.1–157.9]; P = 0.001) improved statistically, but below clinical relevance thresholds. Time below range (TBR) < 70 mg/dL increased (2.7% [2.6–2.9] to 3.2% [3.1–3.4]; P < 0.001), TBR < 54 mg/dL remained stable (1.7%–1.8%; P = 0.516), and severe hypoglycemia decreased (6.4–4.5/100 patient-years; P < 0.001). No changes were seen in children <6 years. In youth 6 to <12 and 12 to <18 years, TiTR and CV improved most, while TBR increased. BMI-standard deviation score (SDS) increased (0.57 [0.53–0.61] to 0.67 [0.63–0.72]; P < 0.001). Conclusion: After 2 years of AID use, TiTR and CV showed clinically relevant improvements, while TBR < 70 mg/dL increased with stable TBR < 54 mg/dL and severe hypoglycemia decreased. Changes in TIR, SG, and HbA1c were statistically significant but small, yet noteworthy, as glycemia usually deteriorates during adolescence. The increase in BMI-SDS needs to be further investigated.
Authors
- Jantje Weiskorn (ORCID: https://orcid.org/0009-0006-8663-3723)
- Marie‐Anne Burckhardt (ORCID: https://orcid.org/0000-0002-6274-5900)
- Nicole Blauensteiner (ORCID: https://orcid.org/0009-0004-3080-0540)
- Marie Auzanneau (ORCID: https://orcid.org/0000-0002-5906-6579)
- Stefanie Lanzinger (ORCID: https://orcid.org/0000-0002-3789-6459)
- Ulrike Helga Elisabeth Schierloh (ORCID: https://orcid.org/0000-0002-7644-4818)
- Julia Schneidewind (ORCID: https://orcid.org/0000-0003-1436-1707)
- Isa Mayer
Institutions
- Centre Hospitalier de Luxembourg (LU)
- University of Basel (CH)
- Universität Ulm (DE)
- University Hospital Bonn (DE)
- Kinderkrankenhaus auf der Bult (DE)
- Comprehensive Cancer Center Vienna (AT)
- University Children’s Hospital Basel (CH)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Vienna (AT)
- University of Lübeck (DE)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1177/15209156261507763
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00